Physician profile
Eugene Stuart
NPI 1982639811
$1,716.13
in general payments reported to CMS, 2019-2025
18 companies · $182 in 2025
The $182 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $69.91 · 2020: $53.47 · 2021: $243 · 2022: $352 · 2023: $365 · 2024: $450 · 2025: $182.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $997.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $997.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,037.72 | 2019-2025 | Linzess, Viberzi, Mavyret |
| Celgene Corporation | $129.86 | 2021-2024 | Zeposia |
| Pfizer INC. | $126.70 | 2022-2025 | |
| Genzyme Corporation | $89.06 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $67.92 | 2020-2024 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.43 | 2019-2021 | |
| Janssen Biotech, INC. | $42.74 | 2019-2021 | |
| Ferring Pharmaceuticals INC. | $28.05 | 2025 | Rebyota |
| Madrigal Pharmaceuticals | $19.37 | 2024 | Resmetirom |
| Boston Scientific Corporation | $18.50 | 2023 | Advanix Biliary |
| Aimmune Therapeutics, INC. | $17.56 | 2025 | Vowst |
| Merck Sharp & Dohme LLC | $17.24 | 2022 | |
| Nestle Healthcare Nutrition INC. | $16.27 | 2021 | |
| Alfasigma USA, INC. | $16.09 | 2020 | |
| Intercept Pharmaceuticals, INC. | $13.57 | 2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $12.86 | 2021 | |
| Ucb, INC. | $12.77 | 2019 | |
| Romark Laboratories, Lc | $1.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eugene Stuart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.